On 13th June, the Supreme Court of the United States unanimously ruled that human genes could not be patented, either in their natural form or isolated in a laboratory using genetic engineering techniques.
Filed by the Association for Molecular Pathology, this appeal was motivated by the practices of Myriad Genetics, a biomedical company based in the United States with branches worldwide, which sought the exclusive rights to commercial use of the technique perfected by Myriad to detect BRCA1 and BRCA2 genes, to identify the risk of developing breast and ovarian cancer.
Patents for human genes banned with a strong biological basis
The Court ruling stated that “DNA is a product of nature and not patent eligible merely because it has been isolated” (1). Since 1982, isolated genes could be patented. The Myriad case was the first time that the Supreme Court banned this practice, a ruling which was welcomed by the scientific community, which, for many years has claimed that genes are produced by nature. In bioethical terms, this ruling represents a great achievement.
Patents for human genes on the legal code
The decision of the Supreme Court was founded on the legal code relating to patents, and especially on the idea of “patentable subject matter”, which refers to things that can be patented and which American lawmakers describe as being “anything under the sun made by man”. But this definition does not include “products of nature”. Members of the Supreme Court understood isolated genomic The Supreme Court, in turn, was careful to take into account the work of Myriad in the sequencing of the BRCA genes but ruled that “separating genes from genetic material is not an act of invention”.
Nevertheless, this ruling recognizes Myriad’s right to patent man-made products derived from genes, known as synthetic DNA.
The repercussions of this ruling in the economic sphere were anything but minor, with Myriad’s stock market value falling by 6%.
Perhaps one of the most important effects of this decision is the significant reduction in the cost of genetic testing to determine whether an individual carries the BRCA1 and BRCA2 genes, which arose after Myriad lost exclusive control over this genetic material.